ALS drug development lukewarm despite icy hot challenge
This article was originally published in Scrip
Executive Summary
The ALS Ice Bucket Challenge has brought awareness, money and even controversy to a rare disease that is both debilitating and fatal to the 5,600 people diagnosed per year, yet it hasn't poured new drug opportunities into the development pipeline.
You may also be interested in...
Amylyx Drug Slows ALS Progression, Filings Imminent
Amylyx has raised just $75m to date, but that was enough to develop AMX0035 through a Phase II/III trial in which the drug slowed the progression of amyotrophic lateral sclerosis versus placebo.
ITF Pharma Plans October US Roll-Out Of Liquid Riluzole Formulation For ALS
Early engagement with US payers suggests openness to covering a liquid form of riluzole, because the tablet version is proven, but it's impossible to take for many ALS patients, says Italfarmaco subsidiary ITF Pharma.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.